**Name of Journal: *World Journal of Clinical Cases***

**Manuscript NO: 48191**

**Manuscript Type: ORIGINAL ARTICLE**

***Retrospective Study***

**HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer**

KaitoA *et al*. HER2 heterogeneity in gastric cancer

**Akio Kaito, Takeshi Kuwata, Masanori Tokunaga, Kohei Shitara, Reo Sato, Tetsuo Akimoto, Takahiro Kinoshita**

**Akio Kaito, Masanori Tokunaga, Reo Sato, Takahiro Kinoshita,** Department of Gastric Surgery, National Cancer Center Hospital East, Kashiwa 277-8577, Japan

**Akio Kaito, Takeshi Kuwata,** Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa 277-8577, Japan

**Takeshi Kuwata, Kohei Shitara,** Exploratory Oncology Research & Clinical Trial Center (EPOC), National Cancer Center Hospital East, Kashiwa 277-8577, Japan

**Akio Kaito,** **Kohei Shitara,** Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan

**Tetsuo Akimoto,** Juntendo University Graduate School of Medicine, Tokyo 163-8001, Japan

**Tetsuo Akimoto,**Department of Radiation Oncology, National Cancer Center Hospital East, Kashiwa 277-8577, Japan

**ORCID number:** Akio Kaito (0000-0003-0839-5695); Takeshi Kuwata (0000-0003-0044-953X); Masanori Tokunaga (0000-0002-3183-349X); Kohei Shitara (0000-0001-5196-3630); Reo Sato (0000-0002-2841-0728); Tetsuo Akimoto (0000-0003-0881-1345); Takahiro Kinoshita (0000-0001-7365-8733).

**Author contributions:** Kaito A and Kuwata T contributed equally to this work in study conception, study design, data acquisition, quality control of data and algorithms, and data analysis and interpretation; Kaito A contributed to statistical analysis and manuscript preparation; All authors contributed equally to manuscript editing and manuscript review.

**Institutional review board statement:** This study was approved by the Institutional Review Board of the National Cancer Center, Japan, No. 2017-164, approval date: Oct. 11, 2017.

**Informed consent statement:** Comprehensive informed consent including publication without personally identifiable information was obtained from all of the subjects prior to study enrollment. Thus, specified informed consent for this study is not required. The public document of this study was published on our website: https://www.ncc.go.jp/jp/about/research\_promotion/study/list/2017-164.pdf. Informed consent statement could not be obtained because most of the participants were deceased.

**Conflict-of-interest statement:** The authors have no conflict of interest to declare.

**Open-access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding author: Takeshi Kuwata, MD, PhD, Doctor,** Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa 277-8577, Japan. tkuwata@east.ncc.go.jp

**Telephone:** +81-4-71331111

**Fax:** +81-4-71300190

**Received:** April 13, 2019

**Peer-review started:** April 15, 2019

**First decision:** May 16, 2019

**Revised:** June 16, 2019

**Accepted:** June 26, 2019

**Article in press:**

**Published online:**

**Abstract**

***BACKGROUND***

The clinical significance of intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity is unclear for HER2-positive gastric cancer, although it has been reported to be a significant prognosticator for HER2-positive breast cancer, which has received trastuzumab-based chemotherapy.

***AIM***

To clarify the clinical significance of intratumoral HER2 heterogeneity for HER2-positive gastric cancer, which has received trastuzumab-based chemotherapy.

***METHODS***

Patients with HER2-positive unresectable or metastatic gastric cancer who received trastuzumab-based chemotherapy as a first line treatment were included. The patients were classified into two groups according to their intratumoral HER2 heterogeneity status examined by immunohistochemistry (IHC) on endoscopic biopsy specimens before treatment, and their clinical response to chemotherapy and survival were compared.

***RESULTS***

A total of 88 patients were included in this study, and HER2 heterogeneity was observed in 23 (26%) patients (Hetero group). The overall response rate was significantly better in patients without HER2 heterogeneity (Homo group) (Homo *vs* Hetero: 79.5% *vs* 35.7%, *P* = 0.002). Progression-free survival of trastuzumab-based chemotherapy was significantly better in the Homo group (median, 7.9 *vs* 2.5 mo, HR: 1.905, 95%CI: 1.109-3.268). Overall survival was also significantly better in the Homo group (median survival time, 25.7 *vs* 12.5 mo, HR: 2.430, 95%CI: 1.389-4.273). Multivariate analysis revealed IHC HER2 heterogeneity as one of the independent poor prognostic factors (HR: 3.115, 95%CI: 1.610-6.024).

***CONCLUSION***

IHC of HER2 heterogeneity is the pivotal predictor for trastuzumab-based chemotherapy. Thus, HER2 heterogeneity should be considered during the assessment of HER2 expression.

**Key words:** Human epidermal growth factor receptor 2; Heterogeneity; Trastuzumab; Gastric cancer; Chemotherapy

**© The Author(s) 2019.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Although intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity has been reported as an important predictor of trastuzumab-based chemotherapy for HER2-positive breast cancer, the clinical significance of HER2 heterogeneity for gastric cancer had been unclear. We defined intratumoral HER2 heterogeneity as biopsy specimens were taken from two or more different portions of the tumor that showed different HER2 positivity by immunohistochemistry, and HER2 heterogeneity based on this definition was a pivotal poor predictor of tumor shrinkage and poor prognosticator. Thus, intratumoral HER2 heterogeneity should be included in the assessment of HER2 positivity.

Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. *World J Clin Cases* 2019; In press

**INTRODUCTION**

Human epidermal growth factor receptor 2 (HER2) was introduced as a predictive biomarker for the treatment of gastric cancer along with trastuzumab[1], and trastuzumab was subsequently recommended to be administered for HER2-positive gastric cancer as a molecular target drug[2,3]. Assessment of HER2 expression was performed by immunohistochemistry (IHC) and in-situ hybridization (ISH), where positive HER2 expression was defined as 3+ on IHC or 2+ on IHC with ISH positive[4]. The strong HER2 intensity of IHC 3+ was reported as a better prognostic factor for HER2-positive gastric cancer treated with trastuzumab-based chemotherapy[1].

The frequency of intratumoral HER2 heterogeneity was reported as 45%-79% by IHC and 23%-54% by ISH for HER2-positive gastric cancers[5-8], which were more frequent than that with HER2-positive breast cancers[9]. Although intratumoral HER2 heterogeneity was reported to be one of the poor predictors for treatment response and poor prognosticator for patients with HER2-positive breast cancer who received trastuzumab-based chemotherapy[10,11], the clinical significance of intratumoral HER2 heterogeneity for HER2 positive gastric cancer treated with trastuzumab has not been well investigated. Recently, Wakatsuki *et al*[12] reported that intratumoral HER2 heterogeneity had a negative survival benefit for patients with surgically resected HER2-positive gastric cancer. However, HER2 assessment before treatment is usually based on the endoscopic biopsy specimen for metastatic gastric cancer, and the clinical significance of intratumoral HER2 heterogeneity for biopsy specimen is still unknown.

The aim of this study was to clarify the clinical significance of intratumoral HER2 heterogeneity for HER2 positive gastric cancer treated with trastuzumab-based chemotherapy by evaluation of biopsy specimens.

**MATERIALS AND METHODS**

***Patients and data collection***

Patients with histologically confirmed HER2-positive metastatic or unresectable adenocarcinoma of the stomach or gastroesophageal junction cancer who received trastuzumab-based chemotherapy as first-line treatment at our hospital between July 2011 and December 2017 were included in this study. The patients were classified into two groups according to intratumoral HER2 heterogeneity, and their clinicopathological findings, clinical responses, progression-free survival (PFS) and overall survival (OS) were compared. Furthermore, the predictive factor for clinical response and prognostic factor were analyzed using multivariable analyses. We extracted clinicopathological findings such as age, sex, tumor diameter, tumor location, macroscopic tumor type, tumor markers, Eastern Cooperative Oncology Group performance score, TNM stage, metastatic site, chemotherapy regimen, histological type of endoscopic biopsy specimen, HER2 positivity, survival outcomes from our prospectively collected database and medical records. Biopsied specimens stained by IHC were reviewed and assessed for their intratumoral HER2 heterogeneity by two pathologists (A.K. and T.K.).

Patients who received gastrectomy prior to chemotherapy and patients who received chemotherapy without trastuzumab were excluded. Clinical response was evaluated according to new response evaluation criteria in solid tumors (RECIST guideline ver. 1.1) for patients with measurable metastatic lesions[13]. The onset of PFS was defined as the start of chemotherapy, and tumor progression was evaluated by imaging techniques and physical examination. Tumor progression dates for patients who received radical gastrectomy after good clinical response to chemotherapy were defined as the date of first recurrence after surgery. Tumor staging of gastric and EGJ type III tumor followed the Union for International Cancer Control TNM classification of 7th edition for gastric cancer, and tumor staging of EGJ type II tumor followed that for esophageal cancer[14]. Tumor histology was assessed according to the Japanese Classification of Gastric Carcinoma[15], with well and moderately differentiated adenocarcinoma and papillary adenocarcinoma classified as differentiated type, and poorly differentiated adenocarcinoma, signet ring cell carcinoma, and mucinous carcinoma classified as undifferentiated type.

***Treatment schedules***

Chemotherapy regimens were capecitabine or 5-fluorouracil plus cisplatin with trastuzumab (XPT/FPT) before September 2015 and S-1 plus oxaliplatin with trastuzumab (SOXT) after October 2015. XPT or FPT regimens were followed a ToGA study regimen[1]. SOXT regimen was followed according to the G-SOX study regimen in combination with trastuzumab; oxaliplatin was administered intravenously 100 mg/m2 on day 1, while S-1 was administered orally 80 mg/ m2 for 14 d followed by a 7-d rest. This schedule was repeated every 3 wk. Trastuzumab was given by intravenous infusion at a dose of 8 mg/kg on day 1 of the first cycle, followed by 6 mg/kg every 3 wk until disease progression[16].

***HER2 immunohistochemistry and fluorescence in situ hybridization***

All endoscopic biopsy samples were fixed in neutral buffered 10% formalin. Formalin-fixed paraffin-embedded tumor samples were examined for HER2 using IHC and fluorescence in situ hybridization (FISH) when the HER2 score was 2+.

HER2 IHC analyses were performed using the PATHWAY anti-HER-2/neu (4B5) rabbit monoclonal primary antibody (Ventana Medical Systems, Tucson, AZ, United States). IHC HER2 scoring by biopsy specimen was performed as described in the ToGA study[1]. In brief, tumor cell clusters of at least five positive cells with complete basolateral or lateral membranous reactivity was considered HER2-positive for endoscopic biopsy samples irrespective of percentage of tumor cells stained. Tumor cells with strong membranous reactivity were scored 3+, and those with moderate reactivity were scored 2+. HER2 FISH analyses were performed at SRL (Tokyo, Japan) using the Path Vysion HER2 DNA Probe kit (Vysis, Downers Grove, IL, United States). When the ratio of HER2 signals to chromosome 17 centromere signals was 2.0 or greater, the gene was considered amplified (*i.e.* FISH-positive). HER2 positivity was defined as IHC score 3+ or IHC score 2+ and FISH positivity, because these criteria were considered to be indications for using trastuzumab by a subset analysis of the ToGA trial[1,3].

***Assessment of intratumoral HER2 heterogeneity***

Assessment of intratumoral HER2 heterogeneity was conducted on patients who underwent assessment of HER2 positivity from two or more different portions of the same tumor, and three or more biopsy specimens were obtained from each portion. Those patients whose HER2 assessment was performed from only one portion were excluded for further examination. Intratumoral HER2 homogeneity was defined as every portion being HER2-positive by IHC, and if any portion of the tumor was HER2-negative, the tumor was defined as intratumoral HER2 heterogeneity (Figure 1).

***Statistical analysis***

The baseline characteristics of each group were compared using the χ2 test or the Fisher’s exact test for categorical data, and *P* < 0.05 was considered statistically significant. The median OS rate and PFS rate were estimated by the Kaplan-Meier method. Independent prognostic factors for OS and PFS were evaluated by univariate and multivariable analysis of Cox proportional hazard model and presented as hazard ratio and 95% confidence interval (CI). Evaluated factors in multivariable analysis were those that were significant by univariate analysis. Data were censored on May 31, 2019. All statistical analyses were performed using SPSS Statistics 20 (SPSS Inc., Chicago, IL, United States).

This study was approved by the Institutional Review Board of the National Cancer Center, Japan (IRB file No. 2017-164, approval date: Oct. 11, 2017).

**RESULTS**

A total of 776 patients with metastatic or unresectable adenocarcinoma of the stomach or gastroesophageal junction were treated in this study period, and HER2 positivity was observed in 127 cases (16.3%). Of these, patients who received upfront gastrectomy before chemotherapy (*n* = 5) or chemotherapy without trastuzumab (*n* = 21), and patients who underwent HER2 assessment from only one portion of the tumor (*n* = 13) were excluded (Figure 2). Finally, a group of 88 patients were evaluated for intratumoral HER2 heterogeneity, in which HER2 homogeneity was observed in 65 (Homo group) and HER2 heterogeneity was observed in 23 (Hetero group) patients.

Patients’ backgrounds are shown in Table 1. Intratumoral HER2 heterogeneity was significantly more frequently observed in macroscopically type 3 and type 4 patients than other types, and in patients with IHC 2+ compared to IHC 3+. Other background characteristics such as age, sex, performance status, TNM stage, metastatic site and chemotherapeutic regimens were not significantly different between the groups. Besides, the number of biopsy sites for HER2 assessment was not significantly different, *i.e.* those numbers more than three was 46% for Homo group and 57% for Hetero group (*P* = 0.393). Waterfall plot for tumor shrinkage and clinical responses for the patients with measurable metastatic lesions (*n* = 58) of both groups are shown in Figure 3. Overall response rate (complete response and partial response) was 79.5% in the Homo group, which was considerably better than that in the Hetero group (35.7%, *P* = 0.002). Kaplan-Meier curves of OS and PFS in both groups are shown in Figure 4. At the time of the analysis, the median follow-up was 18.5 mo (range, 4.7-88.0 mo). The median survival time (MST) in the Hetero group was 12.5 mo, which was considerably worse than that in the Homo group (25.7 mo, HR; 2.430, 95%CI: 1.389-4.273). Median PFS time in the Hetero group was 2.9 mo, which was also significantly worse than that in the Homo group (7.9 mo, HR: 2.000, 95%CI: 1.203-3.333). Multivariate analysis revealed IHC HER2 heterogeneity as one of the independent poor prognostic factors for OS (HR: 3.115, 95%CI: 1.610-6.024) and PFS (HR: 2.123, 95%CI: 1.225-3.676) (Table 2). Undifferentiated histological type (HR: 2.612, 95%CI: 1.388-4.916), number of non-curative factors (HR: 2.252, 95%CI: 1.113-4.553), clinical nodal status (HR: 2.119, 95%CI: 1.165-3.855), hepatic metastasis (HR: 2.084, 95%CI: 1.076-4.036) and HER2 score (2+) (HR: 2.008, 95%CI: 1.094-3.690) were also extracted as independent poor prognostic factors for OS. We compared survival results by the combination of each HER2 score (2+ or 3+) and HER2 heterogeneity (homogeneity or heterogeneity). MST for the Homo group with HER2 3+ was longest (28.2 mo), followed by Hetero group with 3+ (14.6 mo) and Homo group with 2+ (12.9 mo). Hetero group with 2+ had the worst prognosis (MST: 7.2 mo) (Figure 5).

**DISCUSSION**

In this study, we examined the effect of intratumoral HER2 heterogeneity by IHC for HER2-positive advanced gastric cancer treated with trastuzumab-based chemotherapy on their therapeutic responses and survival. Intratumoral HER2 heterogeneity by IHC evaluated by biopsy specimen before treatment was one of the independent poor predictive factors for tumor shrinkage and a poor prognosticator.

The definition of intratumoral HER2 heterogeneity for HER2-positive gastric cancer has not been well established. The cut-off value between HER2 homogeneity and heterogeneity of HER2 positive tumor cells varies from 50% to 100% for surgically resected specimens[5,6,12,17] and 30% to 100% for endoscopic biopsy specimens[7,8,18]. The clinical significance of intratumoral HER2 heterogeneity for HER2-positive gastric cancer treated with trastuzumab has not been well investigated, and there have been only a few studies conducted to date. Wakatsuki *et al*[12] defined the cut-off value of HER2 heterogeneity as 100% and reported that HER2 homogeneity group had significantly longer PFS (HR: 0.11, 95%CI: 0.03-0.41) and OS (HR: 0.18, 95%CI: 0.06-0.72). However, their study included only 28 patients who received trastuzumab-based chemotherapy after upfront gastrectomy for resectable gastric cancer, not metastatic cancer.

In post hoc exploratory analyses of the ToGA trial, the proportion of HER2-positive tumor cells in more than 30% of biopsy specimens could not be extracted as a predictive factor for good response to trastuzumab-based chemotherapy[18]. Yagi *et al*[8] recently reported that intratumoral HER2 heterogeneity was a poor predictor for trastuzumab-based chemotherapy and a poor prognosticator with the cut-off value of 100% from the median number of four biopsy specimens. Our current study selected patients in whom HER2 positivity could be assessed from more than two different portions of the tumor, and we defined HER2 heterogeneity as any of those tumor portions being negative for HER2. The number of biopsy specimens examined for each patient in our current study was more than six (*i.e.* each of the three fragments were obtained from two or more different portions). Although Yagi *et al*[8] adopted the overall proportion of HER2-positive tumor cells to evaluate intratumoral HER2 heterogeneity, we employed the standard criteria of HER2 positivity generally performed in clinical diagnosis, *i.e.* tumor cell cluster of at least five positive cells with complete basolateral or lateral membranous reactivity. According to our simple definition of intratumoral HER2 heterogeneity, the treatment outcomes were definitively different between the HER2 homogeneity group and heterogeneity group.

The stain intensity for IHC was reported as a significant prognostic factor for HER2-positive gastric cancer in the ToGA trial. The OS was significantly longer in IHC 3+ patients than IHC 2+ patients (MST: 17.9 and 12.3 mo)[1]. Assessment of HER2 positivity for endoscopic biopsy specimen in the ToGA trial was established without consideration of intratumor HER2 heterogeneity, which is now commonly adopted worldwide[4]. Prognostic significance of stain intensity for IHC was also explored in combination with heterogeneity for IHC in our current study. MST of Homo-IHC 3+ patients was 28.2 mo, which was much better than MST of IHC 3+ patients (17.9 mo) in the ToGA trial. Hetero-IHC 3+ and Homo-IHC 2+ patients had comparable survival (14.6 and 12.9 mo), while Hetero-IHC 2+ patients had poorer survival (7.2 mo) compared to IHC 2+ patients (12.3 mo) in the ToGA trial. These results suggest that intratumoral HER2 heterogeneity should be included in the assessment of HER2 positivity in addition to the stain intensity for IHC, and patients with Homo-IHC 3+ might be the most responsive to further anti-HER2 agents. The survival benefits for anti-HER2 drugs such as lapatinib or pertuzumab in combination with trastuzumab and adjuvant therapy of trastuzumab or trastuzumab beyond progression have been demonstrated for breast cancers[19-22]. However, the efficacy of those anti-HER2 agents has not been shown for gastric cancers, and intratumoral HER2 heterogeneity may be one of the reasons for the difference of these results between breast and gastric cancers[23,24].

Although the intrinsic mechanism underlying the correlation between HER2 heterogeneity and poor efficacy of trastuzumab-based chemotherapy is still unclear, chemo-resistance can be one of the main reasons for the treatment failure. Fabi *et al*[25] reported that the discordances of HER2 positivity between primary and metastatic lesions may be a possible cause of chemo-resistance of trastuzumab for metastatic breast cancers. Park *et al*[26] reported these discordances between primary and metastatic lesions could also be observed in HER2-positive gastric cancers, and HER2 heterogeneity of primary lesions existed in such cases with discordances of HER2 positivity. Another explanation for the poor efficacy of trastuzumab might be genomic alterations. Pietrantonio *et al*[27] reported that chemo-resistance against trastuzumab was more frequently observed in patients with genomic alternations including *EGFR*/*MET*/*KRAS*/*PI3K*/*PTEN* mutations than those without. They stated such genomic mutations were correlated with IHC 2+, *i.e.* the existence of HER2 heterogeneity.

 Our study has several limitations. First, concordance of intratumoral HER2 heterogeneity between endoscopic biopsy specimen and whole tumor tissues was not investigated in the current study. The concordance of HER2 positivity between biopsy specimens and surgically resected specimens was reported to be 80%-91% for IHC 3+ and 25%-57% for IHC 2+ patients[28-30], thus the interpretation of HER2 heterogeneity for IHC 2+ patients must be made with care. In breast cancer, similar results have been reported comparing core needle biopsy specimens and surgically resected specimens[31], and repeat testing or reflex testing using an alternative assay (IHC or ISH) are recommended for IHC equivocal cases[32]. Secondly, there was no common standard of adequate numbers and portions for the assessment of intratumoral HER2 heterogeneity. In this study, the assessment of intratumoral HER2 heterogeneity was performed from at least two portions of the tumor. Ohno *et al*[33] reported that HER2 positivity was different in different tumor regions, *i.e.* the frequency of HER2 positivity in the biopsy specimen from the superficial spreading portion, ulcer mound, and mass portion was as high as 90% to 100%, while these from ulcer bed was only 45% due to the presence of concomitant necrotic tissues and associated inflammation[34]. These results suggest that the assessment of HER2 heterogeneity should be based on biopsy specimens taken from the appropriate portion of the tumor. Thirdly, this study did not include the intratumoral heterogeneity of *HER2* gene amplification. Intratumoral heterogeneity of *HER2* gene amplification has been reported to be a significant prognostic factors for metastatic or resectable advanced breast cancers[9,11]. The significance of intratumoral heterogeneity of *HER2* gene amplification should also be clarified in further investigations.

In conclusion, intratumoral HER2 heterogeneity by IHC was a significant predictor of clinical response and a poor prognosticator for trastuzumab-based chemotherapy. Thus, intratumoral HER2 heterogeneity would be useful to further stratify patients with HER2-positive gastric cancer, and thus should be taken into account in future clinical trials.

**Article Highlights**

***Research background***

Human epidermal growth factor receptor 2 (HER2) was introduced as a predictive biomarker for the treatment of gastric cancer along with trastuzumab, and the strong HER2 intensity of immunohistochemistry (IHC) 3+ was reported as a better prognostic factor for HER2-positive gastric cancer treated with trastuzumab-based chemotherapy. Intratumoral HER2 heterogeneity for HER2-positive gastric cancers was reported to be more frequent than in HER2-positive breast cancers. Although intratumoral HER2 heterogeneity was reported to be one of the poor predictors for the treatment response and poor prognosticator for patients with HER2-positive breast cancer who received trastuzumab-based chemotherapy, the clinical significance of intratumoral HER2 heterogeneity for HER2-positive gastric cancer treated with trastuzumab has not been well investigated. Furthermore, even the definitions of HER2 heterogeneity for HER2-positive gastric cancer have not been established. In this study, we established the definition of intratumoral HER2 heterogeneity and clarified the clinical significance of HER2 heterogeneity for HER2-positive gastric cancer.

***Research motivation***

HER2 heterogeneity may be a pivotal predictor for the efficacy of trastuzumab-based chemotherapy. Authors have previously reported that intratumoral HER2 heterogeneity had a negative survival benefit for patients with surgically resected HER2-positive gastric cancer. However, HER2 assessment before treatment is usually based on endoscopic biopsy specimen for metastatic gastric cancer, and the clinical significance of intratumoral HER2 heterogeneity for biopsy specimen is still unknown. If these clinical significances are clarified, HER2 heterogeneity might be introduced to the assessment of HER2 positivity for gastric cancer in the future.

***Research objectives***

The aim of this study was to clarify the clinical significance of intratumoral HER2 heterogeneity for HER2-positive gastric cancer treated with trastuzumab-based chemotherapy by evaluation of biopsy specimens.

***Research methods***

Patients with HER2-positive metastatic or unresectable adenocarcinoma of the stomach or gastroesophageal junction who received trastuzumab-based chemotherapy as first-line treatment at our hospital were included. The patients were classified into two groups (Homo- and Hetero- group) according to intratumoral HER2 heterogeneity, and their clinicopathological findings, clinical responses, progression-free survival (PFS) and overall survival (OS) were compared. Furthermore, the predictive factor for clinical response and prognostic factor were analyzed using multivariable analyses. Assessment of intratumoral HER2 heterogeneity was conducted on patients who underwent assessment of HER2 positivity from two or more different portions of the same tumor, and three or more biopsy specimens were obtained from each portion. Those patients whose HER2 assessment was performed from only one portion were excluded. We defined intratumoral HER2 homogeneity as every portion of the tumor being HER2-positive by IHC, and any portion of the tumor staining negative for HER2 was defined as intratumoral HER2 heterogeneity.

***Research results***

A total of 776 patients with metastatic or unresectable adenocarcinoma of the stomach or gastroesophageal junction were treated in the study period, and HER2 positivity was observed in 127 patients (16.3%). Intratumoral HER2 heterogeneity was significantly more frequently observed in macroscopically type 3 and type 4 patients than other types, and patients with IHC 2+ than IHC 3+. Tumor shrinkage and clinical responses for the patients with measurable metastatic lesions were evaluated, and overall response rate (complete response and partial response) was considerably better in the Homo group than in the Hetero group. Median survival time in the Hetero group was 12.5 mo, which was considerably worse than that in the Homo group (25.7 mo, HR; 2.430, 95%CI: 1.389-4.273). Median PFS time in the Hetero group was 2.9 mo, which was also significantly worse than that in the Homo group (7.9 mo, HR: 2.000, 95%CI: 1.203-3.333). Multivariate analysis revealed IHC HER2 heterogeneity as one of the independent poor prognostic factors for OS (HR: 3.115, 95%CI: 1.610-6.024) and PFS (HR: 2.123, 95%CI: 1.225-3.676).

***Research conclusions***

In this study, we examined the effect of intratumoral HER2 heterogeneity by IHC for HER2-positive advanced gastric cancer treated with trastuzumab-based chemotherapy on their therapeutic responses and survival. Intratumoral HER2 heterogeneity by IHC evaluated by biopsy specimen before treatment was one of the independent poor predictive factors for tumor shrinkage and a poor prognosticator. Our current study selected patients in whom HER2 positivity could be assessed from more than two different portions of the tumor, and we newly defined HER2 heterogeneity as any of those portions of the tumor that did not show HER2 positivity. We employed the standard criteria of HER2 positivity generally performed in clinical diagnosis, *i.e.* tumor cell cluster of at least five positive cells with complete basolateral or lateral membranous reactivity. According to our simple definition of intratumoral HER2 heterogeneity, the treatment outcomes were definitively different between the HER2 homogeneity group and heterogeneity group. Assessment of HER2 positivity for endoscopic biopsy specimen in the ToGA trial was established without consideration of intratumor HER2 heterogeneity. Our current study suggests that the combination of heterogeneity and IHC might be beneficial to predict the efficacy of trastuzumab-based chemotherapy.

***Research perspectives***

HER2 heterogeneity is a pivotal predictor for the efficacy of HER2-positive gastric cancers. However, there are still some problems that need to be solved in the future. First, concordance of intratumoral HER2 heterogeneity between endoscopic biopsy specimen and whole tumor tissues has not been investigated in the current study. Secondly, there was no common standard of adequate numbers and portions for the assessment of intratumoral HER2 heterogeneity. Thirdly, this study did not include the intratumoral heterogeneity of HER2 gene amplification. Intratumoral heterogeneity of *HER2* gene amplification has been reported to be one of the significant prognostic factors for metastatic or resectable advanced breast cancers. The significance of intratumoral heterogeneity of *HER2* gene amplification should also be clarified by further investigations. The survival benefits for anti-HER2 drugs such as lapatinib or pertuzumab in combination with trastuzumab and adjuvant therapy of trastuzumab or trastuzumab beyond progression were demonstrated for breast cancers. However, the efficacy of those anti-HER2 agents had not been proven for gastric cancers, and intratumoral HER2 heterogeneity may be considered as one of the reasons for the difference of these results between breast and gastric cancers. If more detailed clinical significance of intratumoral HER2 heterogeneity is solved in the future, anti-HER2 drugs other than trastuzumab can be adopted, and treatment outcomes of HER2-positive gastric cancers would be improved.

**REFERENCES**

1 **Bang YJ**, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 2010; **376**: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-X]

2 **Japanese Gastric Cancer Association.** Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 2017; **20**: 1-19 [PMID: 27342689 DOI: 10.1007/s10120-016-0622-4]

3 **Ajani JA**, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, Denlinger CS, Fanta P, Farjah F, Fuchs CS, Gerdes H, Gibson M, Glasgow RE, Hayman JA, Hochwald S, Hofstetter WL, Ilson DH, Jaroszewski D, Johung KL, Keswani RN, Kleinberg LR, Korn WM, Leong S, Linn C, Lockhart AC, Ly QP, Mulcahy MF, Orringer MB, Perry KA, Poultsides GA, Scott WJ, Strong VE, Washington MK, Weksler B, Willett CG, Wright CD, Zelman D, McMillian N, Sundar H. Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. *J Natl Compr Canc Netw* 2016; **14**: 1286-1312 [PMID: 27697982]

4 **Bartley AN**, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AB 3rd, Carrato A, Gulley ML, Jain D, Kakar S, Mackay HJ, Streutker C, Tang L, Troxell M, Ajani JA. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. *J Clin Oncol* 2017; **35**: 446-464 [PMID: 28129524 DOI: 10.1200/JCO.2016.69.4836]

5 **Lee HE**, Park KU, Yoo SB, Nam SK, Park DJ, Kim HH, Lee HS. Clinical significance of intratumoral HER2 heterogeneity in gastric cancer. *Eur J Cancer* 2013; **49**: 1448-1457 [PMID: 23146959 DOI: 10.1016/j.ejca.2012.10.018]

6 **Kurokawa Y**, Matsuura N, Kimura Y, Adachi S, Fujita J, Imamura H, Kobayashi K, Yokoyama Y, Shaker MN, Takiguchi S, Mori M, Doki Y. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. *Gastric Cancer* 2015; **18**: 691-697 [PMID: 25224659 DOI: 10.1007/s10120-014-0430-7]

7 **Ahn S**, Ahn S, Van Vrancken M, Lee M, Ha SY, Lee H, Min BH, Lee JH, Kim JJ, Choi S, Jung SH, Choi MG, Lee JH, Sohn TS, Bae JM, Kim S, Kim KM. Ideal number of biopsy tumor fragments for predicting HER2 status in gastric carcinoma resection specimens. *Oncotarget* 2015; **6**: 38372-38380 [PMID: 26460823 DOI: 10.18632/oncotarget.5368]

8 **Yagi S**, Wakatsuki T, Yamamoto N, Chin K, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Shinozaki E, Suenaga M, Fujisaki J, Ishikawa Y, Yamaguchi K, Namikawa K, Horiuchi Y. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer. *Gastric Cancer* 2019; **22**: 518-525 [PMID: 30328533 DOI: 10.1007/s10120-018-0887-x]

9 **Lee HJ**, Kim JY, Park SY, Park IA, Song IH, Yu JH, Ahn JH, Gong G. Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab. *Am J Clin Pathol* 2015; **144**: 570-578 [PMID: 26386078 DOI: 10.1309/AJCP51HCGPOPWSCY]

10 **Seol H**, Lee HJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Park SY. Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance. *Mod Pathol* 2012; **25**: 938-948 [PMID: 22388760 DOI: 10.1038/modpathol.2012.36]

11 **Lee HJ**, Seo AN, Kim EJ, Jang MH, Suh KJ, Ryu HS, Kim YJ, Kim JH, Im SA, Gong G, Jung KH, Park IA, Park SY. HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. *Am J Clin Pathol* 2014; **142**: 755-766 [PMID: 25389328 DOI: 10.1309/AJCPIRL4GUVGK3YX]

12 **Wakatsuki T**, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Matsushima T, Suenaga M, Shinozaki E, Hiki N, Ishikawa Y, Yamaguchi K. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. *J Gastroenterol* 2018; **53**: 1186-1195 [PMID: 29633013 DOI: 10.1007/s00535-018-1464-0]

13 **Eisenhauer EA**, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). *Eur J Cancer* 2009; **45**: 228-247 [PMID: 19097774 DOI: 10.1016/j.ejca.2008.10.026]

14 **Sobin LH,** Gospodarowicz MK, Wittekind C. TNM classification of malignant tumors, 7th ed. Wiley-Blackwell, A John Wiley & Sons, Ltd., 2009

15 **Japanese Gastric Cancer Association.** Japanese classification of gastric carcinoma: 3rd English edition. *Gastric Cancer* 2011; **14**: 101-112 [PMID: 21573743 DOI: 10.1007/s10120-011-0041-5]

16 **Koizumi W**, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, Komatsu Y, Tsuburaya A. Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). *Ann Oncol* 2010; **21**: 1001-1005 [PMID: 19875759 DOI: 10.1093/annonc/mdp464]

17 **Motoshima S**, Yonemoto K, Kamei H, Morita M, Yamaguchi R. Prognostic implications of HER2 heterogeneity in gastric cancer. *Oncotarget* 2018; **9**: 9262-9272 [PMID: 29507688 DOI: 10.18632/oncotarget.24265]

18 **Van Cutsem E**, Bang YJ, Feng-Yi F, Xu JM, Lee KW, Jiao SC, Chong JL, López-Sanchez RI, Price T, Gladkov O, Stoss O, Hill J, Ng V, Lehle M, Thomas M, Kiermaier A, Rüschoff J. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. *Gastric Cancer* 2015; **18**: 476-484 [PMID: 25038874 DOI: 10.1007/s10120-014-0402-y]

19 **Johnston SRD**, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams LS, Gradishar WJ. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. *J Clin Oncol* 2018; **36**: 741-748 [PMID: 29244528 DOI: 10.1200/JCO.2017.74.7824.]

20 **Swain SM**, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortés J; CLEOPATRA Study Group. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. *N Engl J Med* 2015; **372**: 724-734 [PMID: 25693012 DOI: 10.1056/NEJMoa1413513]

21 **Gianni L**, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. *Lancet Oncol* 2014; **15**: 640-647 [PMID: 24657003 DOI: 10.1016/S1470-2045(14)70080-4]

22 **von Minckwitz G**, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, Baumann KH, Clemens MR, Duerr R, Uleer C, Andersson M, Stein RC, Nekljudova V, Loibl S. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. *J Clin Oncol* 2009; **27**: 1999-2006 [PMID: 19289619 DOI: 10.1200/JCO.2008.19.6618]

23 **Tabernero J**, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, Kang YK. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. *Lancet Oncol* 2018; **19**: 1372-1384 [PMID: 30217672 DOI: 10.1016/S1470-2045(18)30481-9]

24 **Satoh T**, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, Tsuji A, Omuro Y, Li J, Wang JW, Miwa H, Qin SK, Chung IJ, Yeh KH, Feng JF, Mukaiyama A, Kobayashi M, Ohtsu A, Bang YJ. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. *J Clin Oncol* 2014; **32**: 2039-2049 [PMID: 24868024 DOI: 10.1200/JCO.2013.53.6136]

25 **Fabi A**, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, Ercolani C, Ferretti G, Melucci E, Buglioni S, Sperduti I, Papaldo P, Cognetti F, Mottolese M. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. *Clin Cancer Res* 2011; **17**: 2055-2064 [PMID: 21307144 DOI: 10.1158/1078-0432.CCR-10-1920]

26 **Park SR**, Park YS, Ryu MH, Ryoo BY, Woo CG, Jung HY, Lee JH, Lee GH, Kang YK. Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER2 reassessment study 1 (GASTHER1). *Eur J Cancer* 2016; **53**: 42-50 [PMID: 26693898 DOI: 10.1016/j.ejca.2015.09.018]

27 **Pietrantonio F**, Fucà G, Morano F, Gloghini A, Corso S, Aprile G, Perrone F, De Vita F, Tamborini E, Tomasello G, Gualeni AV, Ongaro E, Busico A, Giommoni E, Volpi CC, Laterza MM, Corallo S, Prisciandaro M, Antista M, Pellegrinelli A, Castagnoli L, Pupa SM, Pruneri G, de Braud F, Giordano S, Cremolini C, Di Bartolomeo M. Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. *Clin Cancer Res* 2018; **24**: 1082-1089 [PMID: 29208673 DOI: 10.1158/1078-0432.CCR-17-2781]

28 **Yoshida H**, Yamamoto N, Taniguchi H, Oda I, Katai H, Kushima R, Tsuda H. Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. *Virchows Arch* 2014; **465**: 145-154 [PMID: 24889042 DOI: 10.1007/s00428-014-1597-3]

29 **Fazlollahi L**, Remotti HE, Iuga A, Yang HM, Lagana SM, Sepulveda AR. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens. *Arch Pathol Lab Med* 2018; **142**: 516-522 [PMID: 28782986 DOI: 10.5858/arpa.2017-0039-OA]

30 **Kanayama K**, Imai H, Yoneda M, Hirokawa YS, Shiraishi T. Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: A comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. *Cancer Sci* 2016; **107**: 536-542 [PMID: 26752196 DOI: 10.1111/cas.12886]

31 **Tsuda H**, Kurosumi M, Umemura S, Yamamoto S, Kobayashi T, Osamura RY. HER2 testing on core needle biopsy specimens from primary breast cancers: interobserver reproducibility and concordance with surgically resected specimens. *BMC Cancer* 2010; **10**: 534 [PMID: 20925963 DOI: 10.1186/1471-2407-10-534]

32 **Wolff AC**, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, Press MF, Spears PA, Vance GH, Viale G, Hayes DF; American Society of Clinical Oncology; College of American Pathologists. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. *J Clin Oncol* 2013; **31**: 3997-4013 [PMID: 24101045 DOI: 10.1200/JCO.2013.50.9984]

33 **Oono Y**, Kuwata T, Takashima K, Yoda Y, Ikematsu H, Shitara K, Kinoshita T, Yano T. Clinicopathological features and endoscopic findings of HER2-positive gastric cancer. *Surg Endosc* 2018; **32**: 3964-3971 [PMID: 29500656 DOI: 10.1007/s00464-018-6138-8]

34 **Gullo I**, Grillo F, Molinaro L, Fassan M, De Silvestri A, Tinelli C, Rugge M, Fiocca R, Mastracci L. Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer. *Endosc Int Open* 2015; **3**: E165-E170 [PMID: 26135662 DOI: 10.1055/s-0034-1391359]

**P-Reviewer:** Chen S, Cao ZF, Cao J **S-Editor:** Dou Y

**L-Editor:** Filipodia **E-Editor:**

**Specialty type:** Medicine, Research and Experimental

**Country of origin:** Japan

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**Figure 1** **Assessment of intratumoral HER2 heterogeneity.** Assessment of intratumoral HER2 heterogeneity was conducted from at least two different portions of the same tumor, and more than three biopsy specimens were obtained from each portion. Homogeneity was defined by all assessed portions showing HER2 positivity, and heterogeneity was defined as a tumor with any portions that did not show HER2 positivity. HER2: Human epidermal growth factor receptor 2.



**Figure 2 Patient flow chart.** HER2 positivity was observed in 127 (16.3%) of 776 patients with metastatic or unresectable adenocarcinoma. After exclusion of 39 patients for the listed reasons, HER2 homogeneity was observed in 65 (Homo group) and HER2 heterogeneity was observed in 23 (Hetero group). HER2: Human epidermal growth factor receptor 2.



**Figure 3 Clinical response for patients with or without intratumoral human epidermal growth factor receptor 2 heterogeneity.** Tumor shrinkage (left) and clinical response (right) was evaluated by RECIST ver. 1.1 for 58 patients who have measurable metastatic lesions. ORR was 79.5% in the Homo group, which was significantly higher than that in the Hetero group (35.7%, *P* = 0.002). CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; ORR: Overall response rate (CR plus PR).



**Figure 4 OS and PFS with or without intratumoral human epidermal growth factor receptor 2 heterogeneity.** Kaplan-Meier curves of OS (left) and PFS (right) in both groups was shown with the median follow-up of 18.5 mo (range, 4.7-88.0 mo). MST and median PST in the Hetero group were significantly worse than those in the Homo group.MST: Median survival time; HR: Hazard ratio; CI: Confidence interval; OS: Overall survival; PFS: Progression-free survival.



**Figure 5 Overall survival by HER2 score and intratumoral HER2 heterogeneity.** MST for the Homo group with HER2 3+ was longest (28.2 mo), followed by Hetero group with 3+ (14.6 mo), Homo group with 2+ (12.9 mo) and Hetero group with 2+ (7.2 mo).MST: Median survival time; HR: Hazard ratio; CI: Confidence interval; HER2: Human epidermal growth factor receptor 2.

**Table 1** **Patients’ demographic information**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Homo, *n* = 65** | **Hetero, *n* = 23** | ***P*-value** |
| Age in yr | 69 (42-81) | 67.0 (45-82) |  |
| < 70 | 34 (52%) | 15 (65%) | 0.284 |
| ≥ 70 | 31 (48%) | 8 (35%) |  |
| Sex |
| Male | 43 (66%) | 18 (78%) | 0.279 |
| Female | 22 (34%) | 5 (22%) |  |
| ECOG performance status |
| 0 | 61 (94%) | 20 (87%) | 0.152 |
| 1 | 2 (3%) | 3 (13%) | (0 *vs* ≥ 1) |
| 2 | 2 (3%) | 0 |  |
| Macroscopic type |
| 1 | 7 (11%) | 1 (5%) | 0.008 |
| 2 | 28 (43%) | 4 (17%) | (type 1/2 *vs* 3/4) |
| 3 | 23 (35%) | 16 (69%) |  |
| 4 | 7 (11%) | 2 (9%) |  |
| Tumor location |
| Upper | 27 (42%) | 11 (48%) | 0.601 |
| Middle / lower | 38 (58%) | 12 (52%) |  |
| Histology |
| Well differentiated | 48 (74%) | 14 (61%) | 0.31 |
| Poorly differentiated | 15 (23%) | 9 (39%) |  |
| Other/unknown | 2 (3%) | 0 |  |
| T status |
| cT2 | 2 (3%) | 0 | 0.267 |
| cT3 | 17 (26%) | 4 (17%) | (cT2/3 *vs* cT4) |
| cT4 | 46 (71%) | 19 (83%) |  |
| N status |
| cN0 | 5 (8%) | 2 (9%) | 0.748 |
| cN1 | 5 (8%) | 1 (4%) | (≤cN2 *vs* cN3) |
| cN2 | 32 (49%) | 11 (48%) |  |
| cN3 | 23 (35%) | 9 (39%) |  |
| Number of non-curative factor |
| 0 | 1 (1%) | 1 (4%) | 0.404 |
| 1 | 32 (49%) | 13 (57%) | (≤1 *vs* >1) |
| 2 | 29 (45%) | 9 (39%) |  |
| >2 | 3 (5%) | 0 |  |
| Non-curative factor |
| Lymph node | 34 (52%) | 10 (43%) |  |
| Peritoneal | 22 (34%) | 6 (26%) |  |
| Hepatic | 27 (42%) | 12 (52%) |  |
| Other | 9 (14%) | 1 (5%) |  |
| Number of HER2 assessment |
| 2 | 35 (54%) | 10 (43%) | 0.393 |
| 3 | 27 (42%) | 13 (57%) |  |
| >3 | 3 (4%) | 0 |  |
| HER2 score |
| 3+ | 53 (82%) | 10 (43%) | 0.001 |
| 2+ | 12 (18%) | 13 (57%) |  |
| Upfront chemotherapy |
| SOXT | 33 (50%) | 12 (52%) |  |
| XPT | 25 (37%) | 7 (30%) |  |
| SPT | 3 (5%) | 2 (9%) |  |
| FPT | 1 (2%) | 2 (9%) |  |
| FLT | 1 (2%) |  |  |
| PTXT | 1 (2%) |  |  |
| DCST | 1 (2%) | 　 | 　 |

ECOG: Eastern Cooperative Oncology Group; SOXT: S-1 oxaliplatin capecitabine trastuzumab; XPT: capecitabine cisplatin trastuzumab; SPT: S-1 cisplatin trastuzumab; FPT: 5-Fluorouracil cisplatin trastuzumab; FLT: 5-Fluorouracil leucovorin trastuzumab; PTXT: Paclitaxel trastuzumab; DCST: Docetaxel cisplatin S-1 trastuzumab.

**Table 2** **Prognostic factors for overall survival and progression-free survival**

|  |  |  |
| --- | --- | --- |
| **Covariates** | **Overall survival** | **Progression-free survival** |
| **Univariate analysis** | **Multivariable analysis** | **Univariate analysis** | **Multivariable analysis** |
| **HR (95%CI)** | ***P*-value** | **HR (95%CI)** | ***P*-value** | **HR (95%CI)** | ***P*-value** | **HR (95%CI)** | ***P*-value** |
| Age, ≥ 80 *vs* < 80 | 1.31 (0.473-3.625) | 0.604 |  |  | 1.138 (0.492-2.633) | 0.762 |   |   |
| Sex, female *vs* male | 1.057 (0.621-1.798) | 0.838 |   |   | 1.005 (0.615-1.642) | 0.985 |   |  |
| Macroscopic type, type 3,4 *vs* 1,2 | 1.72 (1.027-2.881) | 0.039 |   |   | 1.641 (1.037-2.598) | 0.034 |  |  |
| Clinical tumor depth, cT4 *vs* ≤ cT3 | 1.838(0.992-3.405) | 0.053 |   |   | 1.408 (0.826-2.401) | 0.209 |  |  |
| Clinical nodal status, cN3 *vs* ≤ cN2 | 2.026 (1.184-3.466) | 0.01 | 2.119 (1.165-3.855) | 0.014 | 1.691 (1.056-2.708) | 0.029 | 1.622 (0.951-2.764) | 0.076 |
| Histology, undiff. *vs* diff. | 1.884 (1.090-3.255) | 0.023 | 2.612 (1.388-4.916) | 0.003 | 1.643 (1.031-2.618) | 0.037 | 1.902 (1.117-3.237) | 0.018 |
| HER2 score, 2+ *vs* 3+ | 2.331 (1.353-4.016) | 0.002 | 2.008 (1.094-3.690) | 0.024 | 1.828 (1.110-3.012) | 0.018 | 1.612 (0.940-2.770) | 0.083 |
| HER2 heterogeneity, hetero *vs* homo | 2.439 (1.389-4.274) | 0.002 | 3.115 (1.610-6.024) | 0.001 | 2 (1.203-3.333) | 0.008 | 2.123 (1.225-3.676) | 0.007 |
| No. of non-curative factors, ≥ 2 *vs* 1 | 1.904 (1.138-3.186) | 0.014 | 2.252 (1.113-4.553) | 0.024 | 1.875 (1.185-2.965) | 0.007 | 1.871 (1.023-3.424) | 0.042 |
| M1, lymph node | 0.687 (0.410-1.150) | 0.154 |  |  | 0.568 (0.358-0.902) | 0.017 |  |  |
| M1, peritoneal | 1.207 (0.699-2.086) | 0.5 |  |  | 1.327 (0.828-2.127) | 0.24 |  |  |
| M1, hepatic | 1.902 (1.141-3.173) | 0.014 | 2.084 (1.076-4.036) | 0.029 | 1.974 (1.244-3.132) | 0.004 | 2.053 (1.151-3.664) | 0.015 |

HER2: Human epidermal growth factor receptor 2; HR: Hazard ratio.